COMMUNIQUÉS West-GlobeNewswire

-
Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP
08/07/2025 -
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
08/07/2025 -
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
08/07/2025 -
Certara Announces Expansion of Clinical Technology Collaboration with Merck
08/07/2025 -
Alignment Healthcare Wins Key Legal Victory: Arizona Medicare Advantage Plans Elevated to 4 Stars
08/07/2025 -
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
08/07/2025 -
SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)
08/07/2025 -
Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report
08/07/2025 -
SRX Health Completes $7.3 Million Financing Led by Insiders and Existing Investors and Announces Financial Commitment of Up to $50 Million
08/07/2025 -
SlimJaro Botanical Approaches Gain Interest in 2025 for Inflammation-Related Metabolic Wellness
08/07/2025 -
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment
08/07/2025 -
Microbot Medical® to Open Inaugural Endovascular Robotics Session at the Society of Robotic Surgery Annual Meeting
08/07/2025 -
Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy
08/07/2025 -
Glucotrack Announces Repurchase of Series A Warrants
08/07/2025 -
QHS Healthcare, Powered by QHSLab, Inc. (OTCQB: USAQ), Opens Doors in Miami to Expand Access to Mental Health Services
08/07/2025 -
Highridge to Introduce activL® Lumbar Disc
08/07/2025 -
Clover Health to Report Second Quarter 2025 Financial Results on August 5, 2025
08/07/2025 -
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
08/07/2025 -
BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis
08/07/2025
Pages